Globally, more than 1.4 million new prostate cancer cases were diagnosed in 2020 (PMID 35252092) and Advanced Prostate Cancer (PCa) comprises approximately 1% of all deaths in the United States each year (PMID 36633525). While androgen deprivation therapy (ADT) can be effective against many prostate cancers, resistance to therapy causes most PCa deaths. Lethal prostate cancers become resistant to ADT and other therapies through a variety of cellular pathways and mechanisms. The field is making advances to overcome resistance to existing chemotherapies, hormone therapies, immunotherapies, and radiation and radioligand-based therapies. The development of new targeted therapies will further help to meet the challenge of treating therapy resistant PCa.
BMC Cancer has published this Collection to better understand resistance mechanisms and develop new therapies for advanced prostate cancer. Topics of interest included, but were not limited to, the following:
- Understanding resistance mechanisms against ADT and taxane chemotherapies
- Involvement of the tumor microenvironment in ADT/chemotherapy efficacy/resistance
- Biomarkers of resistance and treatment outcomes
- Mechanisms of metastasis
- Development of targeted therapies
- Identification of genetic and epigenetic targets for prostate cancer
- Overcoming the immunosuppressive tumor environment and development of effective immunotherapies in prostate cancer
Image credit: Pissanu / stock.adobe.com